Näytetään tulokset 1 - 10 / 654
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML:the HOVON-SAKK-132 trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1182/bloodadvances.2020003855
Dutch-Belgian Hemato-Oncology Coop; Swiss Grp Clinical Canc Res SAKK; Löwenberg, Bob; Pabst, Thomas;...
Blood advances2021 Julkaisujen tiedon ikoni

Model Checking a C plus plus Software Framework:A Case Study

Vertaisarvioitu
DOI
10.1145/3338906.3340453
Lång, John; Prasetya, I. S. W. B.
ACM Joint Meeting on European Software Engineering Conference (ESEC)/ Symposium on the Foundations o...2019 Julkaisujen tiedon ikoni

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Vertaisarvioitu
DOI
10.1182/blood-2018-10-879643
Swiss Grp Clinical Canc Res; Nordic Lymphoma Grp; Zucca, Emanuele; Rondeau, Stephanie; Vanazzi, Anna...
Blood2019 Julkaisujen tiedon ikoni

"Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Avoin saatavuus
DOI
10.1038/s41375-022-01537-w
Rasmussen, Bengt; Gohring, Gudrun; Bernard, Elsa; Nilsson, Lars; Tobiasson, Magnus; Jadersten, Marti...
Leukemia2022 Julkaisujen tiedon ikoni

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Avoin saatavuus
DOI
10.3324/haematol.2018.194399
Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Räty, Rii...
Haematologica: the hematology journal2018 Julkaisujen tiedon ikoni

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Vertaisarvioitu
Avoin saatavuus
DOI
10.1002/gcc.70029
Rasmussen, Bengt; Nilsson, Lars; Tobiasson, Magnus; Jädersten, Martin; Garelius, Hege; Dybedal, Ingu...
Genes chromosomes and cancer2025 Julkaisujen tiedon ikoni

Bounded and compact Toeplitz plus Hankel matrices

Vertaisarvioitu
Avoin saatavuus
DOI
10.4064/sm200806-6-10
Ehrhardt, Torsten ; Hagger, Raffael ; Virtanen, Jani A.
Studia Mathematica2021 Julkaisujen tiedon ikoni

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Vertaisarvioitu
DOI
10.1182/blood-2016-03-704023
Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Räty, Riikka; Gronbaek, Kirsten; Sundb...
Blood2016 Julkaisujen tiedon ikoni

Obesity = physical activity plus dietary intake plus sleep stages plus light exposure

Vertaisarvioitu
DOI
10.3109/07853890.2014.932921
Partonen, Timo
ANNALS OF MEDICINE2014 Julkaisujen tiedon ikoni

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Vertaisarvioitu
DOI
10.1056/NEJMoa2012971
DiNardo, C. D.; Jonas, B. A.; Pullarkat, V.; Thirman, M. J.; Garcia, J. S.; Wei, A. H.; Konopleva, M...
The new england journal of medicine2020

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML:the HOVON-SAKK-132 trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1182/bloodadvances.2020003855
2021

Model Checking a C plus plus Software Framework:A Case Study

Vertaisarvioitu
DOI
10.1145/3338906.3340453
2019

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Vertaisarvioitu
DOI
10.1182/blood-2018-10-879643
2019

"Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Avoin saatavuus
DOI
10.1038/s41375-022-01537-w
2022

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Avoin saatavuus
DOI
10.3324/haematol.2018.194399
2018

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Vertaisarvioitu
Avoin saatavuus
DOI
10.1002/gcc.70029
2025

Bounded and compact Toeplitz plus Hankel matrices

Vertaisarvioitu
Avoin saatavuus
DOI
10.4064/sm200806-6-10
2021

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Vertaisarvioitu
DOI
10.1182/blood-2016-03-704023
2016

Obesity = physical activity plus dietary intake plus sleep stages plus light exposure

Vertaisarvioitu
DOI
10.3109/07853890.2014.932921
2014

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Vertaisarvioitu
DOI
10.1056/NEJMoa2012971
2020